Related Experiment Video
Updated: Apr 1, 2026

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
Published on: September 19, 2025
Shifting the Evolving CAR T Cell Platform into Higher Gear
Daniel R Holohan1, James C Lee1, Jeffrey A Bluestone1
1UCSF Diabetes Center and Department of Medicine, University of California, San Francisco, 513 Parnassus Avenue, Box 0540, San Francisco, CA 94143, USA.
Abstract:
In this issue of Cancer Cell, Zhao and colleagues test various chimeric antigen receptor (CAR) T cells to show that CD28-CD3ζ CAR T cells that constitutively express 4-1BBL promote T cell expansion and tumor eradication while reducing exhaustion. The results have important implications for the development of effective CAR T cell therapies in cancer patients.
Related Concept Videos
Forced Transdifferentiation
Artificial...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
M-Cdk Drives Transition Into Mitosis
iPS Cell Differentiation
Transmission Shafts: Problem Solving
Next, use bending moment diagrams for the shaft to...
Cell Migration

